Trial Outcomes & Findings for Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease (NCT NCT02162979)
NCT ID: NCT02162979
Last Updated: 2018-03-30
Results Overview
TERMINATED
PHASE2
2 participants
2 weeks
2018-03-30
Participant Flow
Documentation regarding the randomization of the two enrolled participants cannot be located. Therefore no meaningful data are available for entry in the data tables.
Participant milestones
| Measure |
Viagra
subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
sildenafil: sildenafil 50mg BID for 2 weeks
|
Placebo Comparator
subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
Placebo
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 2 weeksOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 4 weeks"on" time is the period in which the subject is symptom free. We will track the amount of time the subject is considered symptom free before and after treatment. This value will be represented as a percent change.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 7 weeksOutcome measures
Outcome data not reported
Adverse Events
Viagra
Placebo Comparator
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Tonya Hamilton, reszearch Compliance Auditor
Loma Linda University
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place